Clinical Trials Logo

Clinical Trial Summary

LIFE-BTK PK is a prospective, single-arm, open-label, non-blinded, non-randomized sub-study of LIFE-BTK Randomized Controlled Trial (NCT04227899), that will enroll approximately 7 subjects in the United States (US) and outside the US with a maximum of 5 sites in the US. Of the 7 subjects planned to be enrolled, 4 subjects will be treated with Esprit BTK in below the knee artery(ies) in whom drug-coated balloons (DCB) were not used; 3 subjects will be treated with Esprit BTK in below the knee artery(ies) in whom DCB were used for treatment of inflow disease.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05208905
Study type Interventional
Source Abbott Medical Devices
Contact
Status Active, not recruiting
Phase N/A
Start date February 10, 2022
Completion date February 22, 2028

See also
  Status Clinical Trial Phase
Terminated NCT02287974 - Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin Phase 1/Phase 2
Active, not recruiting NCT03006770 - Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization Phase 3
Completed NCT00987363 - Intraarterial Infusion of Autologous Bone Marrow in Diabetic Patients With Chronic Ischemia of Lower Limbs (CLI) no Revascularization Phase 1/Phase 2
Not yet recruiting NCT02538978 - Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System Phase 3
Completed NCT01408381 - Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia (CLI). Phase 2
Recruiting NCT04849325 - IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease N/A
Completed NCT01257776 - Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients Phase 1/Phase 2
Active, not recruiting NCT04227899 - LIFE-BTK Randomized Controlled Trial N/A
Terminated NCT03111238 - The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM Phase 3
Terminated NCT03174522 - The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM Phase 3
Completed NCT01386216 - Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI) Phase 1
Available NCT03886506 - Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
Available NCT03746899 - Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)